Long-term follow-up of peripheral lymphocyte subsets in a cohort of multiple sclerosis patients treated with natalizumab
| العنوان: | Long-term follow-up of peripheral lymphocyte subsets in a cohort of multiple sclerosis patients treated with natalizumab |
|---|---|
| المؤلفون: | T. Koudriavtseva, Giovanna D'Agosto, Paola Cordiali-Fei, Elisabetta Trento, E. Sbardella, Valentina Bordignon |
| المصدر: | Clinical and Experimental Immunology. 176:320-326 |
| بيانات النشر: | Oxford University Press (OUP), 2014. |
| سنة النشر: | 2014 |
| مصطلحات موضوعية: | Adult, Male, Multiple Sclerosis, Endothelium, T cell, Lymphocyte, Immunology, Antibodies, Monoclonal, Humanized, Immunophenotyping, Leukocyte Count, Immune system, Natalizumab, medicine, Humans, Immunologic Factors, Immunology and Allergy, Retrospective Studies, business.industry, Multiple sclerosis, Middle Aged, medicine.disease, Lymphocyte Subsets, Peripheral, Phenotype, medicine.anatomical_structure, Leukocytes, Mononuclear, Female, business, CD8, Follow-Up Studies, Research Article, medicine.drug |
| الوصف: | Summary Natalizumab, an anti-alpha4 integrin monoclonal antibody inhibiting the adhesion of lymphocytes to the endothelium, is a widely accepted drug treatment for relapsing–remitting multiple sclerosis (RRMS). A peripheral increase of T and B lymphocytes has already been observed as an early treatment effect. This retrospective observational study was aimed to evaluate the peripheral lymphocyte subsets during a long-term treatment follow-up. We included 23 RRMS patients treated with natalizumab for at least 24–48 months who had pretreatment lymphocyte evaluation. Baseline values of lymphocyte subsets and CD4/CD8 ratio did not differ significantly from the 23 matched healthy subjects. The periodic (every 3–6 months) assessment of immune cell subsets was performed by flow cytometry on peripheral blood collected before drug injection. Therapy with natalizumab was confirmed to be effective during the observational period. For all patients, the increase in lymphocytes during natalizumab therapy compared to baseline at every assessment was significantly higher compared to that of overall white blood cells (2·1- and 1·3-fold, respectively, P |
| تدمد: | 1365-2249 0009-9104 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::26e0a6a1f3970f3672c81d1ccee4d276 https://doi.org/10.1111/cei.12261 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....26e0a6a1f3970f3672c81d1ccee4d276 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 13652249 00099104 |
|---|